1 enrolling by invitation. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Enrolling by invitation 1 |
Follow Uveitis: new trials by email Literature Review of Uveitis trials Research Report on Uveitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) RAY121 - Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP) | Phase 1 | Enrolling by invitation | Chugai Pharmaceutical | 144 | 2024-12-09 | 2026-07-17 |
Antiphospholipid Syndrome (1) · Behcet Syndrome (1) · Dermatomyositis (1) · Pemphigoid, Bullous (1) · Purpura, Thrombocytopenic, Idiopathic (1)
Autoimmune Diseases (1) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Cardiovascular Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Connective Tissue Diseases (1) · Cytopenia (1) · Eye Diseases (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhage (1) · Hemorrhagic Disorders (1) · Hereditary Autoinflammatory Diseases (1) · Immune System Diseases (1)
Australia (1) · Austria (1) · Bulgaria (1) · Canada (1) · Croatia (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Japan (1) · Netherlands (1) · Norway (1) · Poland (1) · Portugal (1)